Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1No longer available 1Completed 1Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 3Expanded_access 2

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 31Recurrence 5Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Neoplasm, Residual 1Myasthenia Gravis 1Leukemia, Plasma Cell 1Infections 1Immunoglobulin Light-chain Amyloidosis 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × talquetamab × Clear all
NCT05455320 2026-04-13

MonumenTAL-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
864 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

Celgene

Phase 2 Completed
312 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
23 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05503550 2025-12-16

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

No longer available
Plasma cell

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Approved for marketing
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡